Early AMD associated with coronary heart disease

Article

The results of a study published in the July issue of Ophthalmology has discovered that people in the early stages of age-related macular degeneration (AMD) are at a higher risk of developing coronary heart disease (CHD), offering further support to the theory that AMD is associated with underlying systemic vascular disease.

The results of a study published in the July issue of Ophthalmology has discovered that people in the early stages of age-related macular degeneration (AMD) are at a higher risk of developing coronary heart disease (CHD), offering further support to the theory that AMD is associated with underlying systemic vascular disease.

Tien Yin Wong, MD from Singapore Eye Research Institute and international colleagues conducted a population-based prospective cohort study of 2,228 people free of stroke aged between 69 and 97 years of age, 1,786 of whom were also free of CHD.

Of those free of CHD, 303 developed incident CHD over a seven-year period. It was found that those with early-stage AMD (n=227) had a higher cumulative incidence of CHD than those without, 28.5% versus 18.9%. However, late-stage AMD (n=25) was not associated with incident CHD. Of the total 2,228 persons, 198 developed incident stroke but neither early or late-stage AMD was associated with incident stroke.

It was the conclusion of the authors that people with early-stage AMD do have a higher risk of developing coronary heart disease but not stroke.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.